Drugs / Dopamine
Dopamine
also known as
A-dopamine · Anaerobic Dopamine · ASL-279 · Cardiosteril · Dobutamine a · Dopamin-natterman · Dopamina · Dopamine hcl · +14 more
Small molecule targets ADRB1 via activation
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Neoatricon | — | 2024-05-27 | europa.eu ↗ |
| Label expansion | US (FDA) | DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER | — | 2001-04-17 | fda.gov ↗ |
| Label expansion | US (FDA) | INTROPIN | — | 1981-11-12 | fda.gov ↗ |
| Approved | US (FDA) | INTROPIN | — | 1974-02-25 | fda.gov ↗ |
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06611423 | Oct 2024 → Aug 2025 | impaired renal function disease, systolic heart failure | AstraZeneca | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02053935 | Dec 2013 → Jan 2016 | hyperglycemia, infectious disease with sepsis | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02009007 | Dec 2012 → Jun 2014 | brain hypoxia - ischemia, hypotensive disorder | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1/22 trials · 1 met primary | ||||||
| Phase 1/2 | NCT07214285 | Oct 2025 | Parkinson disease | University Hospital, Lille | Completed | No outcome recorded |
| Phase 1/2 | NCT04332276 | Sep 2020 → May 2024 | Parkinson disease | University Hospital, Lille | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT04525495 | Apr 2020 → Dec 2022 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 32 trials · 2 missed | ||||||
| Phase 3 | NCT01482559 | Feb 2015 → Sep 2017 | hypotensive disorder, intracerebral hemorrhage | University College Cork | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT00314704 | Dec 2003 → Oct 2007 | — | Sepsis Occurrence in Acutely Ill Patients | Completed | Missed primary |
| Phase 46 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT07633600 | Jun 2026 → Jun 2027 expected | — | Jennifer Cutler | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT03892447 | Aug 2019 → Apr 2021 | acute kidney injury | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03170739 | Jun 2017 → Oct 2019 | impaired renal function disease | Tao Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT00484133 | Jun 2007 → Dec 2008 | infectious disease with sepsis | Onze Lieve Vrouwe Gasthuis | Unknown | Missed primary |
| Phase 4 | NCT00115115 | Mar 2004 → Dec 2007 | end stage renal failure | University Medical Center Mannheim | Completed | Met primary |
| Phase not applicable6 trials | ||||||
| — | NCT07667829 | Jun 2026 → Dec 2028 expected | chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| — | NCT02965963 | Dec 2016 → Jun 2025 | — | University of Alberta | Completed | No outcome recorded |
| — | NCT01866657 | Jun 2013 → Nov 2016 | brain hypoxia - ischemia | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded Stop: Business |
| — | NCT01800877 | Apr 2013 → Dec 2014 | hypotensive disorder | Francois Lamontagne | Completed | No outcome recorded |
| — | NCT01722630 | Mar → Jul 2012 | — | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| — | NCT04753008 | Dec 2010 → Mar 2021 | — | Szeged University | Unknown | No outcome recorded |
| Comparator or background therapy35 trials | ||||||
| Phase 1 | NCT00874393 Comparator | Jul 2009 → Dec 2010 | fetal growth restriction, hypotensive disorder | NICHD Neonatal Research Network | Completed | No outcome recorded |
| Phase 2 | NCT05670028 Background | Jun 2023 → Jan 2026 | ischemic stroke, vascular insufficiency disorder | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06784570 Comparator | Jan 2021 → Mar 2024 | left ventricular failure | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT01301313 Comparator | Feb 2011 → Feb 2012 | heart failure | Jose Luis Vazquez Martinez | Terminated | No outcome recorded |
| Phase 2 | NCT01132846 Comparator | Aug 2010 → May 2013 | symptomatic heart failure | Duke University | Completed | No outcome recorded |
| Phase 2/3 | NCT03107858 Comparator | Nov 2017 → Jan 2019 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02428062 Background | Oct 2014 → Dec 2018 | — | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Suspended | No outcome recorded |
| Phase 2/3 | NCT00953303 Comparator | Jan 2009 → Sep 2011 | heart failure | Hebei Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT00628160 Comparator | Oct 2006 → Dec 2012 | cirrhosis of liver, infectious disease with sepsis | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 3 | NCT04750070 Comparator | Aug 2021 → Jul 2025 overdue | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Recruiting | No outcome recorded |
| Phase 3 | NCT04536194 Comparator | Oct 2020 → Aug 2021 | congenital heart disease, infant botulism | Children's Hospital of Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT00604019 Comparator | Mar 2003 → Aug 2009 | infectious disease with sepsis | Rush University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT07322133 Comparator | Jun 2026 → Jun 2027 expected | hypotensive disorder, neonatal respiratory failure, pulmonary hypertension, neonatal | University of California, Davis | Recruiting | No outcome recorded |
| Phase 4 | NCT04243655 Background | Dec 2019 → Oct 2020 | liver disorder | Asian Institute of Gastroenterology, India | Unknown | No outcome recorded |
| Phase 4 | NCT01901809 Comparator | Aug 2013 → Jun 2017 | diastolic heart failure | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT01427686 Comparator | Jun 2011 → Feb 2015 | hypotensive disorder | University of Ulm | Unknown | No outcome recorded |
| Phase 4 | NCT01140399 Comparator | Feb → Jun 2011 | heart failure | Niguarda Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01060293 Comparator | Jul 2009 → Dec 2013 | heart failure | Larissa University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00937092 Comparator | Jan 2009 → Jan 2010 | heart failure | Larissa University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02241083 Comparator | Jun 2006 → May 2014 | head and neck cancer | Tampere University Hospital | Completed | No outcome recorded |
| — | NCT07562932 Comparator | May 2026 → May 2031 expected | cardiogenic shock | Chonnam National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07111442 Background | Aug 2025 → Aug 2028 expected | renal artery atheroma, renovascular hypertension | Peking University First Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07273526 Comparator | Jun → Dec 2025 overdue | infectious disease with sepsis | Laiba Qamar | Recruiting | No outcome recorded |
| — | NCT06447740 Background | Jun 2024 → Jun 2026 overdue | renal artery atheroma, renovascular hypertension | Peking University First Hospital | Recruiting | No outcome recorded |
| — | NCT05064202 Background | Oct 2023 → Oct 2027 expected | cardiogenic shock | Amsterdam UMC, location VUmc | Not yet recruiting | No outcome recorded |
| — | NCT05732077 Background | Jan 2023 → Mar 2025 | renal artery atheroma, renovascular hypertension | Peking University First Hospital | Unknown | No outcome recorded |
| — | NCT04792424 Background | Apr 2021 → May 2022 | — | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT03780686 Comparator | Apr 2017 → Nov 2018 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT03020407 Background | Jan 2017 → Jun 2020 | infectious disease with sepsis | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02730117 Background | Mar 2016 → Jul 2017 | acute kidney injury | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT02742974 Background | Oct 2015 → Nov 2017 | — | CAMC Health System | Terminated | No outcome recorded |
| — | NCT01318278 Comparator | Mar 2011 → Jan 2013 | hypotensive disorder | Baylor College of Medicine | Completed | No outcome recorded |
| — | NCT01882920 Background | Jun 2010 → Jun 2012 | peritoneal neoplasm | Regina Elena Cancer Institute | Completed | No outcome recorded |
| — | NCT00795366 Comparator | Sep 2008 → Sep 2014 | traumatic brain injury | University of Miami | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-02-05 | InBrain Pharma | Results Abstract for AD/PD™ 2026 Alzheimer’s & Parkinson’s Diseases Conference – March 17-21, 2026 inbrainpharma.com ↗
The primary criterion was significantly reduced on A-dopamine compared with oral treatment. |
| 2025-10-08 | InBrain Pharma | Results International Parkinson and Movement Disorder Society 2025 – InBrainPharma Presentation inbrainpharma.com ↗
No tachyphylaxis: sustained efficacy over time on motor symptom control |
| 2025-09-22 | InBrain Pharma | Results InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS 2025 Conference inbrainpharma.com ↗
These long-term results confirm the excellent safety profile of the continuous intracerebroventricular infusion of A-dopamine in advanced parkinsonians refractory to L-dopa and also show a sustainable effect on motor control over time. |
| 2025-07-03 | InBrain Pharma | Regulatory InBrain Pharma receives EMA Positive Scientific Advice supporting Phase 3 clinical development of A-dopamine for the treatment of advanced Parkinson’s disease inbrainpharma.com ↗ |
| 2025-01-25 | Hopstem Biotechnology Inc. | Results 2025【一月精选】领域最新进展 hopstem.com ↗
研究结果显示与口服治疗相比，接受厌氧多巴胺（A-dopamine）治疗的患者该的不自主运动或运动迟缓的时间百分比显著改善，家庭日记也显示出了显著的改善。 |
All press releases naming this drug 7 releases
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 57 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dopamine | “To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or...” NCT05670028 ↗53“Protocol-directed vasopressor administration based on hemodynamic monitoring data. Agents included norepinephrine, phenylephrine, epinephrine, dopamine, and vasopressin.” NCT02742974 ↗ “In the case of CI \<2.5 l/min/m2 and SVI \<35 ml/m2 with SVV\< 15%, an infusion with dopamine was initiated.” NCT01882920 ↗ “Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution” NCT00628160 ↗ “Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine” NCT02730117 ↗ “Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine” NCT04792424 ↗ “dopamine and / or dobutamine and / or milrinone and / or adrenaline” NCT01301313 ↗ “pressor support (noradrenaline, doubutamine, dopamine) as needed” NCT04243655 ↗ “Furosemide; torsemide; nitroglycerin; dopamine; Dobutamine” NCT00953303 ↗ “Enoximone, Dobutamine, Dopamine, Milrinone” NCT05064202 ↗ “Norepinephrine, dopamine, epinephrine” NCT03020407 ↗ |
| Known as | A-dopamine | “The new concept is the intracerebroventricular administration of anaerobic dopamine (A-dopamine) using an abdominal pump connected to a subcutaneous catheter implanted in the...” PMID 39775041 ↗ Jan 2025 |
| Known as | Anaerobic Dopamine | “The new concept is the intracerebroventricular administration of anaerobic dopamine (A-dopamine) using an abdominal pump connected to a subcutaneous catheter implanted in the...” PMID 39775041 ↗ Jan 20251“Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine)” NCT07214285 ↗ |
| Known as | ASL-279 | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Cardiosteril | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dobutamine a | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dopamin-natterman | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dopamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dopamine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | DOPAMINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dopamini hydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dopmin | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dynatra | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Inotropin | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Intropin | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Medopa | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Neoatricon | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | NSC-169105 | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | NSC-173182 | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Oxytyramine | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Sabax dopamin | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Selectajet | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Tensamin | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Action | Activate | “Beta-1 adrenergic receptor agonist” CHEMBL59 ↗ |
| Modality | Small molecule | — CHEMBL59 ↗ |
| Route | Intravenous | “dopamine 5μg/kg/min intravenously” NCT00937092 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor agonist” CHEMBL59 ↗ |